Walleye Capital
EBS icon

Walleye Capital’s Emergent Biosolutions EBS Stock Holding History

Walleye Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-700
Closed -$8.65K – 4540
2025
Q4 		$8.65K Sell
700
-3,300
-83% -$35.4K ﹤0.01% 4305
2025
Q3 		$35.3K Sell
4,000
-6,100
-60% -$47.4K ﹤0.01% 4106
2025
Q2 		$64.4K Buy
+10,100
New +$57.8K ﹤0.01% 3952
2025
Q1 		– Sell
-10,900
Closed -$104K – 4446
2024
Q4 		$104K Buy
10,900
+8,900
+445% +$81.7K ﹤0.01% 4120
2024
Q3 		$16.7K Buy
+2,000
New +$18.2K ﹤0.01% 4850
2024
Q1 		– Sell
-200
Closed -$480 – 5510
2023
Q4 		$480 Sell
200
-13,900
-99% -$32.7K ﹤0.01% 4848
2023
Q3 		$47.9K Buy
14,100
+1,500
+12% +$8.31K ﹤0.01% 4203
2023
Q2 		$92.6K Buy
+12,600
New +$117K ﹤0.01% 3457
2022
Q4 		– Sell
-18,300
Closed -$384K – 3291
2022
Q3 		$384K Buy
+18,300
New +$509K 0.01% 1646

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Walleye Capital's EBS Position: Q1 2026 in Review

Walleye Capital sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 4 shares — an estimated $49 sold.

Walleye Capital first reported a position in EBS in Q3 2018 and held it in 16 quarters. The position peaked at $1.36M in Q2 2023. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Walleye Capital reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 4 Emergent Biosolutions shares in Q1 2026, an estimated $49.
  • Walleye Capital first reported a position in Emergent Biosolutions in Q3 2018 and held it in 16 quarters.
  • Walleye Capital's Emergent Biosolutions position peaked at $1.36M in Q2 2023.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.